ALNYLAM PHARMACEUTICALS, INC. : BERNSTEIN CUTS TO MARKET-PERFORM FROM OUTPERFORM; CUTS TARGET PRICE TO $199 FROM $376

Reuters2026/11/02 10:46

By:Reuters

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

TELEVISA <TLEVISACPO.MX>: UBS CUTS TARGET PRICE TO MXN 8.7 FROM MXN 11.2

Reuters•2026/11/10 13:13

VIVMARK RESIDENTIAL <VMRK.N>: UBS RAISES TARGET PRICE TO $74 FROM $71

Reuters•2026/11/10 13:13

Why Is Pi Network Price Up by 10% Today?

CryptoNewsNet•2026/11/10 12:21

TransDigm Sees FY27 EPS $42.06-EPS $42.91 >TDG

Dow Jones•2026/11/10 11:32